AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT02616302 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexlansoprazole
Description: Dexlansoprazole 15 mg, 30 mg, and 60 mg capsules
Study NCT05243290 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Nicotinamide Riboside
Description: The product under investigation, Nicotinamide riboside (NR), is a naturally occurring NAD+ precursor and a member of the vitamin B3 family.
Study NCT05243290 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Visually matching placebo capsules will contain the same inactive ingredients present in the manufactured NR capsules, with the exception of any NR compound.
Study NCT04740918 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Trastuzumab Emtansine
Description: Trastuzumab emtansine 3.6 mg/kg IV infusion
Study NCT04740918 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Trastuzumab Emtansine
Description: Trastuzumab emtansine 3.6 mg/kg IV infusion
Study NCT04740918 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Atezolizumab
Description: Atezolizumab 1200 mg IV infusion
Study NCT04516967 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Avatrombopag
Description: Oral avatrombopag tablet or sprinkle capsule
Study NCT04516967 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo comparator tablet or sprinkle capsule
Study NCT05894577 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Each study arm will contain a placebo comparator. Placebo will look similar to study drug and will be administered via the same route of administration and dose. However, placebo will be an inactive substance, containing no study drug.
Study NCT04740918 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Placebo
Description: Placebo matched to atezolizumab
Study NCT05611177 — intervention group
Intervention type: OTHER
Intervention: machine learning analysis
Description: We will use robust machine learning approaches, such as Random Forest, XGBoost or Neural Networks.
Study NCT06064526 — intervention group
Intervention type: OTHER
Intervention: No intervention
Description: Non-interventional study based on secondary use of hospital medical records
Study NCT06413134 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: TheraPAP
Description: TheraPAP is a novel CPAP-based therapy in which pressure is dropped as much as 5 cmH2O starting at the beginning of inspiration and extending through the end of expiration where it rises back up to the true therapy pressure for a short period. It improves comfort by providing pressure only when it is needed and maintaining it at a low level the rest of the time. Normal CPAP/APAP therapy keeps pressure at the therapy level during the entire breath cycle, except with some alternate approaches where pressure is decreased but only during the expiratory phase.
Study NCT06413134 — intervention group
Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: APAP
Description: Standard CPAP therapy where therapy pressure is automatically adjusted to prevent respiratory events from occurring. The TheraPAP prototype device will be used to operate in the APAP mode in addition to the TheraPAP intervention mode.
Study NCT05503134 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Universal Donor Natural Killer Cells
Description: Six doses of UD-NK cells will be given thrice weekly for two weeks for up to 2 cycles of treatment
Study NCT05792722 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: Prostate capsule-sparing radical cystectomy
Description: Patients randomized to this arm will receive the prostate capsule-sparing surgery performed in the form of standard simple prostatectomy. Patients will also have a cystectomy with one of the following urinary diversions: ileal conduit, Indiana Pouch, or orthotopic neobladder.
Study NCT05792722 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: Nerve sparing radical cystectomy
Description: Patients randomized to this arm will receive the nerve-sparing surgery will be performed in the form of the standard nerve-sparing radical prostatectomy. Patients will also have a cystectomy with one of the following urinary diversions: ileal conduit, Indiana Pouch, or orthotopic neobladder.
Study NCT05556187 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Individualized automated oxygen titration
Description: Automated oxygen titration based on the oxygen saturation during the entire day.
Study NCT06630676 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Control
Description: Brief 4-slide presentation without a separate session for questions and answers
Study NCT06630676 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Education
Description: Patients will review 27 slides that discuss the different etiologies (causes) of back pain, how common they are, what causes them (e.g., wear and tear, trauma), factors that exacerbate and alleviate the pain, how they are diagnosed and treated, and have an opportunity to ask questions.
Study NCT06053411 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Diclofenac
Description: 25 mg capsule
Study NCT06053411 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: curcumin
Description: 2,000 mg tablet
Study NCT05241834 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LOXO-260
Description: Oral
Study NCT05029882 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ABBV-400
Description: Intravenous (IV) Infusion
Study NCT05029882 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Trifluridine/Tipiracil
Description: Oral Tablet
Study NCT05029882 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bevacizumab
Description: IV Infusion
Study NCT04951453 — intervention group
Intervention type: OTHER
Intervention: None (observational)
Description: None (observational)
Study NCT05624957 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lidocaine epinephrine
Description: Under aseptic condition every one litre of fluid irrigation will be mixture with 10 ml of lidocaine 2% and 0.25mg epinephrine and the last one use before end of surgery dexamethasone 8 mg will be added.
Study NCT05624957 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Epinephrin
Description: 0.25 mg epinephrine mixed with one litre of fluid irrigation
Study NCT06218784 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: iN1011-N17 HCl Suspension (Part 1)
Description: Dose: 100 mg b.i.d for 7 days (Multiple Ascending Dose)
Study NCT06218784 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: iN1011-N17 HCl Capsule (Part 1)
Description: Dose: 200, 400, 800 mg b.i.d for 7 days (Multiple Ascending Dose)
Study NCT06240507 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: ultrasound-guided posterior tibial nerve pulsed radiofrequency
Description: The posterior tibial nerve (PTN) was identified with a 5-12 MHz linear ultrasonography (US) probe at the level of the medial malleolus, where it runs posterior to the posterior tibial artery. Using the in-plane technique, a 22-gauge, 10-cm radiofrequency cannula was inserted under US guidance and advanced until the tip was adjacent to the nerve. Pulse radiofrequency was applied at 42°C for 240 s with a pulse width of 20 ms
Study NCT06240507 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: fluoroscopy-guided intralesional radiofrequency thermocoagulation
Description: The painful heel and calcaneal spur were visualized under lateral fluoroscopy. A 22-gauge, 10-cm radiofrequency cannula was inserted and advanced until the needle tip reached the calcaneal spur tip. When the needle tip contacted the spur, local anesthetic was administered through the cannula and radiofrequency ablation was performed at 80°C for 90 s.
Study NCT05894577 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Montelukast
Description: Montelukast sodium is a white to off-white powder. The 10 mg montelukast tablets are beige, rounded square-shaped, biconvex, film-coated tablets. Each tablet contains 10.4 mg of montelukast sodium, which is equivalent to 10 mg montelukast. All packaging will be labeled to indicate that the product is for investigational use.
Study NCT06511011 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Modified Suan ZaoRen Tang-TianWang BuXin Dan
Description: Chinese medicine granules for 6 weeks
Study NCT04064424 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Prevention video advertisement
Description: Skin Cancer Prevention videos
Study NCT04064424 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Prevention images for advertisement
Description: Skin Cancer Prevention images
Study NCT04064424 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: No Advertisement
Description: No skin cancer prevention videos or images were advertised.
Study NCT06289647 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Azithromycin
Description: In study communities randomized to the Azithromycin Continuation arm, all individuals aged 1 month and older will receive a single mass distribution of azithromycin several weeks after the baseline and 36-month monitoring visits. In study communities randomized to Azithromycin Discontinuation, participants will receive no treatment.
Study NCT04145635 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Aortix System
Description: Aortix is a circulatory support device for chronic heart failure patients on medical management who have been hospitalized for acute decompensated heart failure (ADHF) with worsening renal function.
Study NCT06218784 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Capsule (Part 1)
Description: Dose: b.i.d for 7 days
Study NCT06218784 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: iN1011-N17 HCl Capsule (Part 2)
Description: Dose: 400 mg QD
Study NCT05206422 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Doraya Catheter
Description: The Doraya Catheter is a temporary intravenous flow regulator, positioned in the inferior vena cava below the level of the renal veins
Study NCT06218784 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: iN1011-N17 Mesylate Capsule (Part 2)
Description: Dose: 400 mg QD
Study NCT06218784 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: iN1011-N17 HCl Capsule (Part 3)
Description: Dose: 400 mg b.i.d for 14 days
Study NCT05107778 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ASC42 10mg
Description: ASC42 10mg orally once daily;
Study NCT05107778 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ASC42 15mg
Description: ASC42 15mg orally once daily.
Study NCT05107778 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ih PEG-IFN α-2a
Description: ih PEG-IFN α-2a 180μg subcutaneous injection once a week.
Study NCT05107778 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: ih PEG-IFN α-2a
Description: ih PEG-IFN α-2a 180μg subcutaneous injection once a week.
Study NCT06511011 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo granules for 6 weeks
Study NCT05308095 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Controlled hypoglycaemic state while driving
Description: Participants will drive on a designated circuit with a real car on a test track accompanied by a driving instructor. Initially, a euglycaemic state (5.0 - 8.0 mmol/L) is established and blood glucose is then declined to hypoglycaemia (3.0 - 3.5 mmol/L) by administering insulin. Thereafter, blood glucose is raised again to euglycaemia (5.0 - 8.0mmol/L). During the procedure, driving data is recorded. Additionally, eye movement, head pose, facial expression, heart rate, skin conductance, and CGM values are recorded throughout the glycemic trajectory. Participants are blinded to the blood glucose values during the procedure.
Study NCT04651777 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: FF/UMEC/VI
Description: The investigational drug is a single Ellipta inhaler containing 200 ug fluticasone furoate, 62.5 ug umedlidinium and 25 ug vilanterol. The drug is delivered in an Ellipta inhaler in a single dose once daily.
Study NCT04096937 — intervention group
Intervention type: OTHER
Intervention: Focus groups
Description: Focus groups will be conducted with adult stakeholders and with youth in Appalachia. Feedback from the focus groups will guide cultural tailoring of the Journey of Hope in Appalachia intervention for use in a later phase.
Study NCT04812678 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Fasciatherapy
Description: Fasciatherapy, with manual therapy and/or gestual therapy.
Study NCT04812678 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Physiotherapy
Description: Conventional physiotherapy with massage, exercises, electrotherapy, vertebral traction, heat, cold.
Study NCT04812678 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Physiotherapy
Description: Conventional physiotherapy with massage, exercises, electrotherapy, vertebral traction, heat, cold.
Study NCT06079528 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Electromagnetic device
Description: Health wave's generator (Manufactured with Simeds S.r.l. by Machiavelli, Italy, with serial number 11492.) with two separate emission channels and asynchronous operation was employed, along with 100 saved and storable programs that could be altered by the user (intensity, frequency and phase time). The different associated applicators are recognized automatically. Magnetic field strength up to 100 Gauss and output frequency from (1 - 100) Hertz are programmable.
Study NCT06079528 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: visceral manipulation therapy
Description: for the pelvic reproductive organs and their related structures (ligaments and fasciae) was applied one session/week for 12 weeks. Each patient was was advised to evacuate her bladder before starting the treatment session, mobility and motility testing of pelvic organs, together with the assessment of fascial tension, was then performed, with detecting restrictions, treatment was applied according to Hebgen
Study NCT06079528 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: General advice
Description: were directed for both groups in term of the following: Perform pelvic floor exercises regularly ; avoid constipation and straining; treat the cause of any chronic cough and infection of urethra or bladder; stop smoking; maintain a healthy weight; drinking sufficient amounts of healthy fluids (water); decrease the caffeine intake; and decrease the amount of acidic and spicy foods.
Study NCT06079528 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: General advice
Description: were directed for both groups in term of the following: Perform pelvic floor exercises regularly ; avoid constipation and straining; treat the cause of any chronic cough and infection of urethra or bladder; stop smoking; maintain a healthy weight; drinking sufficient amounts of healthy fluids (water); decrease the caffeine intake; and decrease the amount of acidic and spicy foods.
Study NCT06079528 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: pelvic floor muscle training
Description: consisted of 24 sessions of 45-60 min each, twice a week, for 12 weeks. The PFMT was divided into four phases. Proprioceptive (3 weeks): where the woman has gained adequate perception of PFM and performed fast and slow contractions; Simple (3 week): performed with the objective of promoting control of fast and slow contractions associated with small functional exercises; Elaborated (3 week): where the exercise evolved into functional exercises of greater amplitude; and Power (3 week): where the maximum voluntary contraction of the pelvic floor was promoted during efforts. In all sessions, contractions were performed for slow and fast fibers
Study NCT06079528 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: pelvic floor muscle training
Description: consisted of 24 sessions of 45-60 min each, twice a week, for 12 weeks. The PFMT was divided into four phases. Proprioceptive (3 weeks): where the woman has gained adequate perception of PFM and performed fast and slow contractions; Simple (3 week): performed with the objective of promoting control of fast and slow contractions associated with small functional exercises; Elaborated (3 week): where the exercise evolved into functional exercises of greater amplitude; and Power (3 week): where the maximum voluntary contraction of the pelvic floor was promoted during efforts. In all sessions, contractions were performed for slow and fast fibers
Study NCT06218784 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: iN1011-N17 Mesylate Capsule (Part 3)
Description: Dose: 400 mg b.i.d for 14 days
Study NCT06218784 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo Capsule (Part 3)
Description: Dose: b.i.d for 14 days
Study NCT06425731 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Fasting
Description: Participants (Dance for PD, in-person only) will engage in one of their routine weekly dance sessions while a portable indirect calorimeter is used for energy expenditure analysis. Before this session, participants will be asked to fast for at least 4-hours. In this way, participants in this study arm will engage in a self-controlled study design wherein they complete a 4-hour fast before engaging in an oxygen uptake assessment during their routine dance classes. During the 4-hour fasting period, participants will be asked to refrain from eating any food and drinking any beverages except for water.
Study NCT06425731 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: No Intervention
Description: No Intervention
Study NCT05517785 — intervention group
Intervention type: OTHER
Intervention: Motor performance tests
Description: Performance of 5 motor tests: plank, single leg stance test, standing long jump test (broad jump), 4 x 10 agility test and 20 m shuttle run tests (beeps), after taking ADHD drug or not taking the drug before motor tests performance
Study NCT06548672 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BC3195
Description: BC3195 is a novel antibody drug conjugate (ADC) targeting CDH3 (calcium-dependent adhesion 3). The payload, monomethyl auristatin E (MMAE), is a microtubule disrupting agent covalently attached to the antibody via a cleavable dipeptide linker Val-Cit (vc).
Study NCT04736810 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: AK105
Description: IV infusion
Study NCT04736810 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisplatin
Description: IV infusion
Study NCT04736810 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemcitabine
Description: IV infusion
Study NCT04736810 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Anlotinib hydrochloride
Description: Oral administration
Study NCT04846153 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Human-based Quantification of Airway Stenosis
Description: Human-based Quantification of Airway Stenosis From Bronchoscopic Images.
Study NCT04846153 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Computer-based Quantification of Airway Stenosis From Bronchoscopic Images.
Description: Computer-based Quantification of Airway Stenosis From Bronchoscopic Images.
Study NCT05182203 — intervention group
Intervention type: DRUG
Intervention: biologic/targeted therapy
Description: TNF inhibitors or the JAK inhibitors
Study NCT05588804 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Broncho-munal®
Description: 1 capsule daily in the morning on an empty stomach, 30 minutes before meals, for 10 consecutive days
Study NCT05588804 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 1 capsule daily in the morning on an empty stomach, 30 minutes before meals, for 10 consecutive days
Study NCT04663867 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: AngioSafe Peripheral CTO Crossing System
Description: The AngioSafe Peripheral CTO Crossing System is intended to facilitate the intraluminal placement of guidewires beyond stenotic lesions, including chronic total occlusions (CTOs) in the peripheral vasculature.
Study NCT06065956 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Intravenous morphine
Description: Morphine group(an opioid), participants were given intravenous morphine(an opioid) at induction of General Anaesthesia before laryngoscopy and intubation.~The other group,Esmolol group(cardioselective beta blocker), participants were given intravenous esmolol(cardioselective beta blocker) during induction of General Anesthesia before laryngoscopy and intubation.
Study NCT05720078 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Adaptive, two-phase RT
Description: Participants in this arm will be treated with an adaptive, two-phase radiation therapy approach
Study NCT05035186 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Amoxicillin
Description: Anti-H. pylori regimens
Study NCT06428474 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Health education
Description: Oral health education program designed for orphans children
Study NCT05390320 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: PAOO
Description: Periodontally accelerated osteogenic orthodontics will be applied to treat patients with moderate crowding.
Study NCT05390320 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Fixed appliance
Description: Fixed appliances will be applied to treat patients with moderate crowding without any acceleration methods.
Study NCT05107778 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Entecavir
Description: Entecavir 0.5 mg orally once daily.
Study NCT05107778 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Entecavir
Description: Entecavir 0.5 mg orally once daily.